BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 19285278)

  • 1. Thrombosis associated with angiogenesis inhibitors.
    Elice F; Rodeghiero F; Falanga A; Rickles FR
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):115-28. PubMed ID: 19285278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemostatic complications of angiogenesis inhibitors in cancer patients.
    Elice F; Jacoub J; Rickles FR; Falanga A; Rodeghiero F
    Am J Hematol; 2008 Nov; 83(11):862-70. PubMed ID: 18819092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic events in patients with cancer receiving antiangiogenesis agents.
    Zangari M; Fink LM; Elice F; Zhan F; Adcock DM; Tricot GJ
    J Clin Oncol; 2009 Oct; 27(29):4865-73. PubMed ID: 19704059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
    van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
    Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Side effects of anti-angiogenic drugs.
    Elice F; Rodeghiero F
    Thromb Res; 2012 Apr; 129 Suppl 1():S50-3. PubMed ID: 22682133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact.
    Elice F; Rodeghiero F
    Thromb Res; 2010 Apr; 125 Suppl 2():S55-7. PubMed ID: 20434006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers].
    Drouet L
    Pathol Biol (Paris); 2008 Jun; 56(4):195-204. PubMed ID: 18450388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathophysiology of chemotherapy-associated thrombosis].
    Lechner D; Weltermann A
    Hamostaseologie; 2009 Jan; 29(1):112-20. PubMed ID: 19151860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparins and angiogenesis.
    Norrby K
    APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal effects of anti-angiogenesis therapy: update for the internist.
    Gurevich F; Perazella MA
    Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial cell effects of cytotoxics: balance between desired and unwanted effects.
    de Vos FY; Willemse PH; de Vries EG; Gietema JA
    Cancer Treat Rev; 2004 Oct; 30(6):495-513. PubMed ID: 15325031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification for cancer-associated venous thromboembolism.
    Connolly GC; Khorana AA
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):35-47. PubMed ID: 19285271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of coagulation disorders in cancer patients.
    Kvolik S; Jukic M; Matijevic M; Marjanovic K; Glavas-Obrovac L
    Surg Oncol; 2010 Mar; 19(1):e33-46. PubMed ID: 19394816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide and thrombosis. A meta-analysis.
    El Accaoui RN; Shamseddeen WA; Taher AT
    Thromb Haemost; 2007 Jun; 97(6):1031-6. PubMed ID: 17549307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
    Cooney MM; van Heeckeren W; Bhakta S; Ortiz J; Remick SC
    Nat Clin Pract Oncol; 2006 Dec; 3(12):682-92. PubMed ID: 17139319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 18. The prothrombotic state in cancer: pathogenic mechanisms.
    De Cicco M
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):187-96. PubMed ID: 15182825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombosis in multiple myeloma.
    Zangari M; Elice F; Fink L; Tricot G
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic drugs: from bench to clinical trials.
    Quesada AR; Muñoz-Chápuli R; Medina MA
    Med Res Rev; 2006 Jul; 26(4):483-530. PubMed ID: 16652370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.